Sibylle Loibl
ESMO, ASCO, AGO Kommission Mamma (member); Goethe University Frankfurt; GBG Forschungs GmbH · Prof., MD ASCO, ESGO, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Faculty Member, SABCS Faculty member · GBG Forschungs GmbH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sibylle Loibl as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06607757 · Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerGBG Forschungs GmbH · recruiting · CCCA Assessed by Ki67 Drop Below <2.7% From Baseline · principal investigator
- Ph2NCT06201234 · Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerGBG Forschungs GmbH · recruiting · Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation · study chair
- N/ANCT05739591 · Long-term Safety and Efficacy of GBG Study ParticipantsGBG Forschungs GmbH · recruiting · Breast Cancer · study chair
- Ph4NCT03355157 · A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).GBG Forschungs GmbH · completed · Metastatic Breast Cancer · study chair
- Ph2NCT02685059 · Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerGBG Forschungs GmbH · completed · Breast Cancer · principal investigator
- Ph2NCT02387099 · Dose EScalation Induction of EvERolimusGBG Forschungs GmbH · completed · Breast Cancer, Hormone Receptor Positive Tumor · study chair
- Ph3NCT01864746 · A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and SurgeryGBG Forschungs GmbH · completed · Breast Cancer, Hormonreceptor Positive, Her2-normal · principal investigator
- Ph3NCT01773460 · Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneGBG Forschungs GmbH · terminated · Metastatic Breast Cancer · study chair
- Ph2NCT00548899 · Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerGBG Forschungs GmbH · completed · Breast Cancer · study chair
- N/ANCT00196833 · Breast Cancer in Pregnancy Register StudyGBG Forschungs GmbH · unknown · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:39 UTC. The ranking covers the 200 most relevant of 208 PubMed records, and a shared surname and initials can bring in a namesake. All 208 on PubMed
- 2,116 citationsRCR 82.3
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med · 20192,077 citationsRCR 85.1
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med · 20211,463 citationsRCR 83.1
- Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol · 20101,438 citationsRCR 31.7
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med · 20211,410 citationsRCR 78.5
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.N Engl J Med · 20151,289 citationsRCR 36.8
- 1,045 citationsRCR 28.0
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- 861 citationsRCR 24.9